MDG1 — Medigene AG Balance Sheet
0.000.00%
- €0.60m
- -€10.88m
- €6.03m
- 11
- 79
- 38
- 34
Annual balance sheet for Medigene AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 34.7 | 30 | 22.4 | 33.2 | 16.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.469 | 1.58 | 1.04 | 3.24 | 1.03 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 57.7 | 32.7 | 24.2 | 37.3 | 18.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 8.82 | 6.88 | 4.9 | 4.39 | 3.44 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 109 | 74.8 | 59.5 | 51.7 | 31.7 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10.2 | 10.1 | 8.03 | 7.42 | 7.18 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 27.4 | 21.6 | 14.7 | 14.7 | 10.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 81.8 | 53.2 | 44.8 | 37 | 21.1 |
| Total Liabilities & Shareholders' Equity | 109 | 74.8 | 59.5 | 51.7 | 31.7 |
| Total Common Shares Outstanding |